1,754 results on '"Kullberg, B.J."'
Search Results
2. Human resources required for antimicrobial stewardship teams: a Dutch consensus report
3. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
4. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
5. Diagnostic challenges of Lyme borreliosis
6. Classical Borrelia Serology Does Not Aid in the Diagnosis of Persistent Symptoms Attributed to Lyme Borreliosis: A Retrospective Cohort Study.
7. Using routine blood parameters to anticipate clinical outcomes in invasive aspergillosis
8. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, non-neutropenic, adult patients: An update including COVID-19 data
9. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study
10. Identifying platelet-derived factors as amplifiers of B. burgdorferi-induced cytokine production
11. Diagnostic parameters of cellular tests for Lyme borreliosis in Europe (VICTORY study): a case-control study
12. [Conflicts of interest in scientific advisory panels]
13. Concerns about the external validity of the study 'prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort study'-authors´ reply
14. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
15. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)
16. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
17. ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS
18. ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases
19. European expert opinion on the management of invasive candidiasis in adults
20. EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group
21. Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study
22. What is responsible antibiotic use? A search for a multi-stakeholder definition, quality indicators, barriers and facilitators
23. Expectancies as predictors of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease
24. Antimicrobial Stewardship. Appropriate Antibiotic Care from the Patients’ and Professionals’ Perspective
25. Performance of Existing Definitions and Tests for the Diagnosis of Invasive Fungal Diseases other than Invasive Candidiasis and Invasive Aspergillosis in Critically Ill, Adult Patients: A Systematic Review with Qualitative Evidence Synthesis
26. The Initial QuantiFERON-Lyme Prototype is Unsuitable for European Patients
27. Recommendations for antibacterial therapy in adults with COVID-19-an evidence based guideline
28. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
29. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis
30. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
31. Lyme borreliosis: diagnosis and management
32. A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology
33. Quality Indicators for Appropriate Outpatient Parenteral Antimicrobial Therapy in Adults: A Systematic Review and RAND-modified Delphi Procedure
34. Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris
35. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion
36. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
37. Quality of antibiotic use for lower respiratory tract infections at hospitals: (how) can we measure it?
38. The Impact of Nontuberculous Myobacteria on Management of Presumed Pulmonary Tuberculosis
39. Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis
40. Is bij een doorgemaakte endocarditis ook profylaxe bij koorts e.c.i. of bij ‘griep’ geïndiceerd?
41. Is er een relatie tussen Chronisch Vermoeidheidssyndroom en M. Addison?
42. Incidence and outcome of invasive candidiasis in intensive care units (icus) in europe: Results of the eucandicu project
43. An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis
44. Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study
45. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial
46. Prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis: study protocol for an observational, prospective cohort study (LymeProspect)
47. Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis
48. Validation of cellular tests for Lyme borreliosis (VICTORY) study
49. Cognitive impairments in patients with persistent symptoms attributed to Lyme disease
50. A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.